Literature DB >> 19036873

NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3.

Saleh Ismail1, Anne Sturrock, Ping Wu, Barbara Cahill, Kimberly Norman, Thomas Huecksteadt, Karl Sanders, Thomas Kennedy, John Hoidal.   

Abstract

Persistent hypoxia can cause pulmonary arterial hypertension that may be associated with significant remodeling of the pulmonary arteries, including smooth muscle cell proliferation and hypertrophy. We previously demonstrated that the NADPH oxidase homolog NOX4 mediates human pulmonary artery smooth muscle cell (HPASMC) proliferation by transforming growth factor-beta1 (TGF-beta1). We now show that hypoxia increases HPASMC proliferation in vitro, accompanied by increased reactive oxygen species generation and NOX4 gene expression, and is inhibited by antioxidants, the flavoenzyme inhibitor diphenyleneiodonium (DPI), and NOX4 gene silencing. HPASMC proliferation and NOX4 expression are also observed when media from hypoxic HPASMC are added to HPASMC grown in normoxic conditions, suggesting autocrine stimulation. TGF-beta1 and insulin-like growth factor binding protein-3 (IGFBP-3) are both increased in the media of hypoxic HPASMC, and increased IGFBP-3 gene expression is noted in hypoxic HPASMC. Treatment with anti-TGF-beta1 antibody attenuates NOX4 and IGFBP-3 gene expression, accumulation of IGFBP-3 protein in media, and proliferation. Inhibition of IGFBP-3 expression with small interfering RNA (siRNA) decreases NOX4 gene expression and hypoxic proliferation. Conversely, NOX4 silencing does not decrease hypoxic IGFBP-3 gene expression or secreted protein. Smad inhibition does not but the phosphatidylinositol 3-kinase (PI3K) signaling pathway inhibitor LY-294002 does inhibit NOX4 and IGFBP-3 gene expression, IGFBP-3 secretion, and cellular proliferation resulting from hypoxia. Immunoblots from hypoxic HPASMC reveal increased TGF-beta1-mediated phosphorylation of the serine/threonine kinase (Akt), consistent with hypoxia-induced activation of PI3K/Akt signaling pathways to promote proliferation. We conclude that hypoxic HPASMC produce TGF-beta1 that acts in an autocrine fashion to induce IGFBP-3 through PI3K/Akt. IGFBP-3 increases NOX4 gene expression, resulting in HPASMC proliferation. These observations add to our understanding hypoxic pulmonary vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036873      PMCID: PMC2660216          DOI: 10.1152/ajplung.90488.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  70 in total

1.  Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer.

Authors:  Sébastien Le Jan; Nolwenn Le Meur; Aurélie Cazes; Josette Philippe; Martine Le Cunff; Jean Léger; Pierre Corvol; Stéphane Germain
Journal:  FEBS Lett       Date:  2006-05-11       Impact factor: 4.124

2.  Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression.

Authors:  Stephanie McMahon; Martine Charbonneau; Sebastien Grandmont; Darren E Richard; Claire M Dubois
Journal:  J Biol Chem       Date:  2006-06-30       Impact factor: 5.157

Review 3.  The pathology of pulmonary artery hypertension.

Authors:  B Meyrick
Journal:  Clin Chest Med       Date:  2001-09       Impact factor: 2.878

4.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.

Authors:  R C Trembath; J R Thomson; R D Machado; N V Morgan; C Atkinson; I Winship; G Simonneau; N Galie; J E Loyd; M Humbert; W C Nichols; N W Morrell; J Berg; A Manes; J McGaughran; M Pauciulo; L Wheeler
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

5.  Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.

Authors:  N W Morrell; X Yang; P D Upton; K B Jourdan; N Morgan; K K Sheares; R C Trembath
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

Review 6.  Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms.

Authors:  Kurt R Stenmark; Karen A Fagan; Maria G Frid
Journal:  Circ Res       Date:  2006-09-29       Impact factor: 17.367

7.  Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells.

Authors:  Anne Sturrock; Barbara Cahill; Kimberly Norman; Thomas P Huecksteadt; Kenneth Hill; Karl Sanders; S V Karwande; James C Stringham; David A Bull; Martin Gleich; Thomas P Kennedy; John R Hoidal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-10-14       Impact factor: 5.464

8.  Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling.

Authors:  F Viñals; J Pouysségur
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 9.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.

Authors:  Karen Bedard; Karl-Heinz Krause
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 10.  Hypoxia-induced reactive oxygen species formation in skeletal muscle.

Authors:  Thomas L Clanton
Journal:  J Appl Physiol (1985)       Date:  2007-02-08
View more
  89 in total

Review 1.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

2.  Upregulation of Nox4 by TGF{beta}1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat.

Authors:  Xiaoyong Tong; Xiuyun Hou; David Jourd'heuil; Robert M Weisbrod; Richard A Cohen
Journal:  Circ Res       Date:  2010-08-19       Impact factor: 17.367

Review 3.  Redox regulation of vascular remodeling.

Authors:  Keyvan Karimi Galougahi; Euan A Ashley; Ziad A Ali
Journal:  Cell Mol Life Sci       Date:  2015-10-20       Impact factor: 9.261

Review 4.  Reactive oxygen species in inflammation and tissue injury.

Authors:  Manish Mittal; Mohammad Rizwan Siddiqui; Khiem Tran; Sekhar P Reddy; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2013-10-22       Impact factor: 8.401

Review 5.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

6.  Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.

Authors:  Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2019-03-19       Impact factor: 8.401

Review 7.  NADPH oxidase: its potential role in promotion of pulmonary arterial hypertension.

Authors:  Jing-Jie Peng; Bin Liu; Jin-Yun Xu; Jun Peng; Xiu-Ju Luo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

8.  Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology.

Authors:  Norah Alruwaili; Sharath Kandhi; Dong Sun; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2018-12-21       Impact factor: 8.401

Review 9.  NADPH oxidases in lung health and disease.

Authors:  Karen Bernard; Louise Hecker; Tracy R Luckhardt; Guangjie Cheng; Victor J Thannickal
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

10.  The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

Authors:  David E Green; Tamara C Murphy; Bum-Yong Kang; Jennifer M Kleinhenz; Cédric Szyndralewiez; Patrick Page; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2012-08-16       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.